Ryan Deschner analyst RAYMOND JAMES

Currently out of the existing stock ratings of Ryan Deschner, 41 are a BUY (100%).

Ryan Deschner

Work Performance Price Targets & Ratings Chart

Analyst Ryan Deschner, currently employed at RAYMOND JAMES, has had 32.25% of price targets met with an average potential upside of 57.8%, reached in 138 days on average.

Ryan Deschner has documented 79 price targets and ratings displayed on 7 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on SPRY, ARS Pharmaceuticals at 06-Nov-2026.

Wall Street Analyst Ryan Deschner

Analyst best performing recommendations are on LQDA (LIQUIDIA TECHNOLOGIES).
The best stock recommendation documented was for LQDA (LIQUIDIA TECHNOLOGIES) on 10/1/2026. The price target of $53 was fulfilled within 41 days with a profit of $25.01 (89.35%), with a performance score of 21.79.

Average potential price target upside

ARDX Ardelyx LQDA Liquidia Technologies SPRY ARS Pharmaceuticals TRVI Trevi Therapeutics ADMA ADMA Biologics APLS Apellis Pharmaceuticals PVLA

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 17-Apr-2023

$9

$6.01 (201.00%)

$19

3 months 4 days ago
(18-Aug-2026)

7/20 (35%)

$5.08 (129.59%)

247

Buy Since 26-Sep-2025

$15

$12.01 (401.67%)

$19

3 months 5 days ago
(17-Aug-2026)

14/24 (58.33%)

$10.94 (269.46%)

437

Buy Since 03-Mar-2016

$11

$8.01 (267.89%)

$14

3 months 12 days ago
(10-Aug-2026)

8/18 (44.44%)

$7 (175.00%)

307

Buy Since 03-May-2024

$10

$7.01 (234.45%)

$10

3 months 15 days ago
(07-Aug-2026)

0/4 (0%)

$6 (150.00%)

Buy Since 04-Mar-2025

$14

$11.01 (368.23%)

$17

3 months 15 days ago
(07-Aug-2026)

0/7 (0%)

$10 (250.00%)

Show more analysts

Please expand the browser size to see the chart

Which stock is Ryan Deschner most bullish on?

Potential upside of $14.04 has been obtained for SPRY (ARS PHARMACEUTICALS)

Which stock is Ryan Deschner most reserved on?

Potential downside of -$1.43 has been obtained for LQDA (LIQUIDIA TECHNOLOGIES)

What Year was the first public recommendation made by Ryan Deschner?

On 2024
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?